{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T04:31:12Z","timestamp":1723782672590},"reference-count":0,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["eods"],"published-print":{"date-parts":[[2004]]},"DOI":"10.1517\/eods.3.3.187.31073","type":"journal-article","created":{"date-parts":[[2004,5,4]],"date-time":"2004-05-04T14:41:48Z","timestamp":1083681708000},"page":"187-198","source":"Crossref","is-referenced-by-count":1,"title":["Safety of rifampin and pyrazinamide for the treatment of latent tuberculosis infection"],"prefix":"10.1517","volume":"3","author":[{"given":"Jason E","family":"Stout","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","container-title":["Expert Opinion on Drug Safety"],"original-title":[],"language":"en","deposited":{"date-parts":[[2015,4,9]],"date-time":"2015-04-09T23:56:10Z","timestamp":1428623770000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.extenza-eps.com\/extenza\/loadHTML?objectIDValue=31073&type=abstract"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004]]},"references-count":0,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004]]}},"alternative-id":["10.1517\/eods.3.3.187.31073"],"URL":"https:\/\/doi.org\/10.1517\/eods.3.3.187.31073","relation":{},"ISSN":["1474-0338"],"issn-type":[{"value":"1474-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2004]]}}}